Free Trial
NASDAQ:MYNZ

Mainz Biomed 7/1/2025 Earnings Report

Mainz Biomed logo
$2.03 -0.01 (-0.49%)
As of 12:14 PM Eastern

Mainz Biomed EPS Results

Actual EPS
N/A
Consensus EPS
-$2.80
Beat/Miss
N/A
One Year Ago EPS
N/A

Mainz Biomed Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mainz Biomed Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Mainz Biomed Earnings Headlines

Mainz Biomed prices $4M securities offering
The DOJ Just Paved the Way for Account Seizures
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
See More Mainz Biomed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mainz Biomed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mainz Biomed and other key companies, straight to your email.

About Mainz Biomed

Mainz Biomed (NASDAQ:MYNZ) N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

View Mainz Biomed Profile

More Earnings Resources from MarketBeat